Features of interleukin status in patients with type 1 diabetes mellitus

Abstract

A hundred years have passed since the first use of insulin as the main means of therapy for type 1 diabetes mellitus. During this time, significant progress has been made in the development of insulin therapy, including the development of new insulin formulations and methods of its delivery. At the same time, over the years, expanding knowledge about the immunopathogenesis of type 1 diabetes mellitus, doctors are trying to reach a completely new level of possibilities in the treatment of this disease. At this level, methods of immunotherapeutic effects on those links of autoimmune chains will become available, which today limit both the therapy of patients with type 1 diabetes and the development of the idea of stem-cells transplantation due to the lack of a holistic understanding of ways to overcome post-transplant immune aggression against -cells. The review summarizes the current understanding of known interleukins involved as the most important intermediaries in the phases of initiation and immuno-mediated destruction of pancreatic -cells. The achievements in the study of the role of key interleukins in the pathophysiology of autoimmune diabetes for marking potential application points of immunomodulatory targeted therapy are considered.